Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Luo M, Xie P, Deng X, Fan J, Xiong L
Journal
Nutrients
Year
2023
Keywords:
5-HT, bile acids, constipation, gut microbiota, loperamide, metabolites, rifaximin
Structural changes in the gut microbiota are closely related to the development of functional constipation, and regulating the gut microbiota can improve constipation. Rifaximin is a poorly absorbed antibiotic beneficial for regulating gut microbiota, but few studies have reported its effects on constipation. The purpose of this study was to investigate the effect of rifaximin on loperamide-induced constipation in SD rats. The results showed that rifaximin improved constipation by increasing serum 5-HT, SP, and the mRNA expression of AQP3, AQP8, and reducing the mRNA expression of TLR2 and TLR4. In addition, rifaximin could regulate the gut microbiota of constipated rats, such as increasing the potentially beneficial bacteria Akkermansia muciniphila and Lactobacillus murinus, reducing the Bifidobacterium pseudolongum. According to metabolomics analysis, many serum metabolites, including bile acids and steroids, were changed in constipated rats and were recovered via rifaximin intervention. In conclusion, rifaximin might improve loperamide-induced constipation in rats by increasing serum excitatory neurotransmitters and neuropeptides, modulating water metabolism, and facilitating intestinal inflammation. Muti-Omics analysis results showed that rifaximin has beneficial regulatory effects on the gut microbiota and serum metabolites in constipated rats, which might play critical roles in alleviating constipation. This study suggests that rifaximin might be a potential strategy for treating constipation.
Experiment 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Rattus norvegicus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to antibiotic Response to antibiotic,response to antibiotic
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Combination of LOP (loperamide) and RIF (rifaximin) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- CTR (control) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were injected with 0.9% saline.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
- Group 1 sample size Number of subjects in the case (exposed) group
- 7
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 3.5
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 3G and 3H
Description: Histogram of LDA value distribution generated by LEfSe indicating the differences of bacterial communities among three groups after LDA using a threshold score of LDA > 3.5
Abundance in Group 1: increased abundance in CTR (control) group
Revision editor(s): Tosin
Experiment 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Combination of CTR (control) and RIF (rifaximin) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- LOP (loperamide) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were injected subcutaneously with 5 mg kg−1 of body weight loperamide in 0.9% saline solution twice daily at 09:00 am and 5:00 pm for 14 days
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 3G and 3H
Description: Histogram of LDA value distribution generated by LEfSe indicating the differences of bacterial communities among three groups after LDA using a threshold score of LDA > 3.5
Abundance in Group 1: increased abundance in LOP (loperamide) group
Revision editor(s): Tosin
Experiment 3
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Combination of CTR (control) and LOP (loperamide) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- RIF (rifaximin) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- The rats in the RIF group were treated with rifaximin (75 mg kg−1 body weight) by gavage administration one hour after LOP was injected
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 3G and 3H
Description: Histogram of LDA value distribution generated by LEfSe indicating the differences of bacterial communities among three groups after LDA using a threshold score of LDA > 3.5
Abundance in Group 1: increased abundance in RIF (rifaximin) group
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Akkermansia muciniphila | ||
| Akkermansiaceae | ||
| Blautia | ||
| Ruminococcus gauvreauii | ||
| Verrucomicrobiales | ||
| Verrucomicrobiia | ||
| Verrucomicrobiota | ||
| unidentified rumen bacterium RF39 |
Revision editor(s): Tosin
Experiment 4
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- CTR (control) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- LOP (loperamide) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were injected subcutaneously with 5 mg kg−1 of body weight loperamide in 0.9% saline solution twice daily at 09:00 am and 5:00 pm for 14 days
- Group 0 sample size Number of subjects in the control (unexposed) group
- 7
Lab analysis
Statistical Analysis
- Statistical test
- Kruskall-Wallis
- T-Test
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 4A, 4B and 4C
Description: Relative abundances of gut microbiota at the phylum, genus and species level among CTR (control) and LOP (loperamide) groups.
Abundance in Group 1: increased abundance in LOP (loperamide) group
Revision editor(s): Tosin
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 4A, 4B and 4C
Description: Relative abundances of gut microbiota at the phylum, genus and species level among CTR (control) and LOP (loperamide) groups.
Abundance in Group 1: decreased abundance in LOP (loperamide) group
| NCBI | Quality Control | Links |
|---|---|---|
| Ligilactobacillus murinus |
Revision editor(s): Tosin
Experiment 5
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- LOP (loperamide) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- RIF (rifaximin) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- The rats in the RIF group were treated with rifaximin (75 mg kg−1 body weight) by gavage administration one hour after LOP was injected
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 4A, 4B, 4C, Table S1 and Table S2
Description: Relative abundances of gut microbiota at the phylum, genus and species level among LOP (loperamide) and RIF (rifaximin) groups
Abundance in Group 1: increased abundance in RIF (rifaximin) group
Revision editor(s): Tosin
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-10
Source: Figure 4A, 4B, 4C, Table S1 and Table S2
Description: Relative abundances of gut microbiota at the phylum, genus and species level among LOP (loperamide) and RIF (rifaximin) groups
Abundance in Group 1: decreased abundance in RIF (rifaximin) group
Revision editor(s): Tosin
Retrieved from "https://bugsigdb.org/w/index.php?title=37960154&oldid=193912"
